Results 281 to 290 of about 488,286 (382)

Nanomaterial‐Based Precision Medicine for Breast Cancer Diagnosis and Treatment

ChemNanoMat, EarlyView.
This research emphasizes the use of targeted precision medicine in the treatment of breast cancer. Through the integration of diagnosis and therapeutic delivery, nanocarriers are designed to selectively target cancer cells, preserving healthy tissue, thereby improving treatment effectiveness and reducing side effects.
Tanaka Ndongwe, Xavier Siwe Noundou, Gauta Gold Matlou, Stéphanie Bessoles, Johanne Seguin, Cyrille Richard, Nathalie Mignet, Yohann Corvis, Bwalya Angel Witika   +8 more
wiley   +1 more source

Myocardial contractility and performance capacity after magnesium infusions in young healthy persons: A double‐blind, placebo‐controlled, cross‐over study

, 1988
Henrik Rasmussen, R. Videbæk, Thomas Melchior, Peter Aurup, C. Cintin, Niels T. Pedersen   +5 more
openalex   +1 more source

Population Pharmacokinetic and Exposure‐Response Analysis of the Cognitive Effects of TAK‐071 in Participants With Parkinson Disease and Cognitive Impairment

Clinical Pharmacology in Drug Development, EarlyView.
Abstract TAK‐071 is a novel muscarinic M1 positive allosteric modulator under investigation for the treatment of cognitive impairment and falls associated with Parkinson disease (PD). This study evaluated population pharmacokinetics of TAK‐071 following single (1‐160 mg) and multiple (3‐15 mg once daily) oral‐dose TAK‐071 in 112 healthy participants ...
Hongxia Jia, Axel Facius, Rachel Jennings, Yaming Hang, Jaya Padmanabhan, Niraj M. Shanbhag, Brian T. Harel, Arthur Simen, Wei Yin   +8 more
wiley   +1 more source

Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I.
Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S. Bell Lynum, Frank Larsen, Pedro Such, Jessica Madera‐McDonough, Murat Yildirim, Ric M. Procyshyn, Craig Chepke, Julie Passarell   +10 more
wiley   +1 more source

Efficacy and health economics of Bufei Yishen granules in patients with frequent exacerbator phenotype in the stable phase of chronic obstructive pulmonary disease: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. [PDF]

Front Med (Lausanne)
Xiao Q, Wang M, Li Z, Chen T, Li J.
europepmc   +1 more source

Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy

, 1983
R. Stuart‐Harris, Robert Buckman, I.D. Starke, E. Wiltshaw   +3 more
openalex   +1 more source

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Endogenous oxytocin plays an important role in lactation, but its effectiveness as an exogenous galactagogue has been modest due to dose‐limiting side effects related to off‐target effects at the vasopressin V2 receptor. Merotocin (FE 202767) is a short‐acting peptidic oxytocin receptor agonist with the potential to aid mothers experiencing ...
Yu Bagger, Carina Holmqvist, Daniël M. Jonker, Bjarke M. Klein, Lorien E. Urban   +4 more
wiley   +1 more source

Solid Medication Intake in Hospitalised Patients With Dysphagia: A Challenge for Speech and Language Pathologists? [PDF]

Int J Lang Commun Disord
Trapl-Grundschober M, Schneider L, Schulz S, Sollereder S, Teuschl Y, Struhal W, Osterbrink J.   +6 more
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

Open-label placebo for non-specific pain in the emergency department (OLP EM): study protocol for a mixed-method randomised control feasibility study in Switzerland. [PDF]

BMJ Open
Degen B, Szczesna A, Nickel CH, Bingisser R, Gaab J, Minotti B.   +5 more
europepmc   +1 more source